Navigation Links
Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
Date:3/20/2008

NANJING, China, March 20 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the appointment of Mr. Mark Chen, Pei-Chi as Vice President of Marketing and the promotion of Baoxing Zha and Dasheng Sun as the Vice Presidents of Hospital Sales and Retail Sales respectively.

The company also announces that Mr. Yat Ming Chu has resigned as the Vice President of Sales and Marketing, together with the departure of Mr. Eric Wang Lam Cheung as Vice President of Investor Relations.

Mark Chen joins Simcere from the pharmaceutical company Merck & Co's international arm, Merck Sharp & Dohme, where he was most recently the Business Unit Director based in Taiwan. Prior to Merck, Mark held senior management roles at Procter & Gamble Greater China and at Softchina Venture Group, a venture capital firm.

Mr. Boxing Zha joined Simcere in 1996 with over 12 years of hospital sales experience and most recently served as General Manager of Simcere Shanghai. Mr. Dasheng Sun joined Simcere in 2001 and was formerly the General Manager of Business Development with extensive experience in both commercial and retail pharmaceutical sales.

Mr. Jinsheng Ren, Chairman and CEO of Simcere, commented, "On behalf of the board, I want to express our sincere gratitude to Mr. Chu for his contribution and dedication, which spans over ten years at Simcere, and for Mr. Cheung's hard work during and beyond our IPO last year. I wish them both the very best for the future."

Mr. Jinsheng Ren added: "We are delighted to welcome Mr. Chen to our team. Mr. Chen brings valuable expe
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
(Date:5/17/2013)... May 17, 2013 Rust removal is one ... non-metal home items could be damaged. To help rust contractors ... of its no-scrubbing rust remover it called Rusterizer. ... available with 10% discount. , My Cleaning Products explained that ... them or by staining them. The first one, it ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
... ... That Scientists Can Focus on Novel Research , ... (PRWEB) May 20, 2010 -- DNA2.0 , the leading gene synthesis ... in order to provide customers with a seamless experience from gene synthesis to protein expression ...
... surf in colder waters and keep warm for longer, ... wetsuit manufacturer, Spartan. Spartan specialise in wetsuits for ... measurement institute, to understand the science behind how wetsuits ... particular it wanted to improve its windsurfing wetsuits, which ...
... CAMBRIDGE, Massachusetts , May ... SHPGY ), the global specialty biopharmaceutical,company, today announced that ... from NORD. Shire was recognized for its efforts to ... enzyme replacement,therapy (ERT) for the treatment of Type 1 ...
Cached Biology Technology:DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 2DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 3A warmer future for watersports 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 3Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 4Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 5
(Date:5/16/2013)... Northwestern University scientists have shown a gene involved in ... proper function of the circadian clock. , In ... found the gene, called Ataxin-2, keeps the clock responsible ... the gene, the rhythm of the fruit fly,s sleep-wake ... schedule difficult for the fly. , The discovery ...
(Date:5/16/2013)... SPARTANBURG, S.C. , May 16, 2013 /PRNewswire/ ... film in combination with a custom thin film ...  the highest forensic quality roll image in the ... market today. Sherlock, an Appendix F Mobile ID ... provides a 95% reduction in size and weight ...
(Date:5/16/2013)... world are meeting next week in Toronto. The ... latest in research findings about the brain, the ... disorders that affect them., "Canada is a leader ... the best of neuroscience research done here and ... the Canadian Association for Neuroscience. He also reminds ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... 26, 2012  Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ... for 2012. Through their subsidiary, ... dispensing and storage systems, which are designed to ... alternative medicine clinics and doctor,s offices. The systems ...
... , RICHLAND, Wash. The Department of Energy,s ... bringing a lab-developed technology that improves research sample ... Consortium announced today that PNNL is receiving a ... consortium is a nationwide network that encourages federal ...
... by the College of Agricultural Sciences, The Pennsylvania State University, ... for Abstract Submissions: 1 March 2012 -- The Society ... an abstract for presentation at the 45th SSR Annual Meeting ... Links to the following are to be found on ...
Cached Biology News:Medbox, Inc. Announces New Product Line for 2012 2PNNL recognized for technology transfer 2
...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... and high speed homogeneous assay for the ... for screening of inhibitors in a high-throughput ... on a fluorescence superquenching technology that does ... universal platform provides flexibility for assaying any ...
Biology Products: